Irsogladine maleate ameliorates inflammation and fibrosis in mice with chronic colitis induced by dextran sulfate sodium

摘要: Intestinal fibrosis is a common and severe complication of inflammatory bowel disease (IBD), especially Crohn’s (CD). To investigate the therapeutic approach to intestinal fibrosis, we have developed mouse model by administering dextran sulfate sodium (DSS) examining effects irsogladine maleate (IM) [2,4-diamino-6-(2,5-dichlorophenyl)-s-triazine maleate], which has been widely used as an antiulcer drug for gastric mucosa in Japan, on DDS-induced chronic colitis. In this experimental colitis lesion, several pathognomonic changes were found: increased deposition collagen, number profibrogenic mesenchymal cells such fibroblasts (vimentin+, α-SMA−) myofibroblasts α-SMA+) both submucosa colon with infiltrating cells, mRNA expressions collagen type I, transforming growth factor (TGF)-β, matrix metalloproteinase (MMP)-2, tissue inhibitor (TIMP)-1. When IM was administered intrarectally colitis, all these pathological significantly decreased or suppressed, suggesting potential adjunctive therapy fibrosis. could consequently reduce DSS direct indirect effect factors fibroblasts. Therefore, precise should be investigated further.